Browsing Tag
clinical trials
131 posts
Quoin Pharmaceuticals raises up to $104.5M in private placement to fuel its rare disease pipeline
Find out how Quoin Pharmaceuticals secured up to $104.5 million in a milestone-linked private placement to advance its rare disease therapy QRX003 and strengthen investor confidence.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.
BeOne Medicines’ sonrotoclax trial hits primary endpoint in mantle cell lymphoma patients
BeOne Medicines’ sonrotoclax met its primary endpoint in mantle cell lymphoma, with positive Phase 1/2 trial results. Find out what this means for patients.
Can Calluna Pharma’s CAL101 finally change the game for idiopathic pulmonary fibrosis patients?
Calluna Pharma begins Phase 2 AURORA trial of CAL101 in idiopathic pulmonary fibrosis, targeting S100A4 for a novel antifibrotic approach.
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.
vTv Therapeutics begins Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes patients
vTv Therapeutics has launched its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. Find out what this means for patients and investors today.
Why Rocket Pharmaceuticals shareholders are filing suit over adverse event risks in RP-A501
A class action lawsuit claims Rocket Pharmaceuticals misled investors about the safety and effectiveness of its gene therapy. Find out what’s at stake.
Alterity Therapeutics stock surges 33% after ATH434 momentum and FDA fast track designation
Alterity Therapeutics surged 33% after highlighting ATH434’s Phase 2 gains and FDA Fast Track status. Find out why investors are piling in now.
JCR Pharmaceuticals completes global Phase III enrollment for JR-141 targeting Hunter syndrome’s neurological symptoms
JCR Pharmaceuticals completes global Phase III enrollment for JR-141, targeting Hunter syndrome CNS symptoms with its BBB-penetrating enzyme therapy.